

PTO/SB/08A (02-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of collection of information unless it contains a write OAAD contains a collection of information unless it contains a write OAAD co

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Not Yet Known Application Number Substitute for form 1449/PTO Herewith Filing Date INFORMATION DISCLOSURE First Named Inventor King, et al. Not Yet Known STATEMENT BY APPLICANT Art Unit Not Yet Known Examiner Name (Use as many sheets as necessary) 891-A-PCT-US Attorney Docket Number of 2 Sheet 1

	Ta		of 2		Attorney	
Sheet	1		01 12			
				U. S. PATENT	DOCUMENTS Name of Patentee or	Pages, Columns, Lines, Where
xaminer	Cite No.1	Documen	nt Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
nitials*	No.'	Number-Kind	Code ^{2 (if known)}	15.0005	Lin, et al.	
/G.K.		us- 6,855,695	5 B2	02-15-2005	Lin, et al.	
		US-				
		US-				
	 	US-				
	+	US-				
	+	US-				
	+	US-			 	
		US-				
		US-				
	 	US-				
		US-				
	+	US-				
	+-	US-				
		US-				
ļ		US-				
		US-				
	i .	US-				

		US-					
	L		IGN PATEN	TDOCUM	MENTS	Columns Lines	_
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Public	ate	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Т
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					╞
	 						╁
							t
	-						I
							L
	+					1	_

		Date	05/08/2008
Examiner	10 10 - 17 2 - 1 1	Considered	
Signature	/Ganapathy Krishnan/	w line through	citation if not in conformance and not
4.5	the development citation is in conformance with Mr El Conformance	designation DUD	ther (optional). See kinds Codes of

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant. Applicant is unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to the two-letter code (WIPO Standard ST.3). For USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For USPTO Patent Documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document of the year of the reign of the Emperor must precede the serial number of the patent document of the year of the reign of the Emperor must precede the serial number of the patent document of the year of the reign of the year of the year of the reign of the year of year

Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, used to proceed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the Chief Information Officer, U.S. Department of Commerce, Washington, DC 20231. TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/593217

PTO/SB/08B (02-03) Approved for use through 04/30/2003. OMB 0651-0031

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995	s, no persons are	e required to respond to a collection	to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitute for form 1449/PTO	1	Application Number	Not Yet Known		
INFORMATION DISCLO	SURE	Filing Date	Herewith		
STATEMENT BY APPL	ICANT	First Named Inventor	King, et al.		
January		Art Unit	Not Yet Known		
(Use as many sheets as necessar	Y)	Examiner Name	Not Yet Known		
Sheet 2 of 2		Attorney Docket Number	891-A-PCT-US		
onder 2					

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Include name of the author (in CAPITAL LETTERS), title of Include name of the author (in CAPITAL LETTERS), title of Include name of the author (in CAPITAL LETTERS), title of Include name of the author (in CAPITAL LETTERS), title of Include name of the author (in CAPITAL LETTERS), title of Include name of the author (in CAPITAL LETTERS), title of Include name of the author (in CAPITAL LETTERS), title of Include name of the	T ²
Examiner Initials*	Cite No. ¹	the item (book, magazine, journal, serial, symposium, dutaley, dutaley, the item (book, magazine, journal, serial, symposium, dutaley, dut	1
/G.K./	1	PCT International Search Report for VION Pharmaceuticals, et al., Int'l Application No. PC17052003/010132, Filed March 25, 2005, Dated March 21, 2006	
/G.K./	2	LEE, et al., "Toxicological evaluation of 1,2 bis("methylsulfonyl)-1-(2-chloroethyl)-2 (methylaminocarbonyl) hydrazine (VNP40101M), novel alkylating Agent with Potential Antitumor Activity, with Intravenous Administration in Rats and Dogs", International Journal of Toxicology, Vol. 23, Pages 23-39 (2002)	
/G.K./	3	Ishiguro, et al., "Role of 0-alkylguanine-DNA alkyltransferase in the cytotoxic activity of clorezatine, iviol Cancer Ther, Vol. 4 (11), Pages 1755-1763 (2005)	
/G.K./	4	Murren, et al., "A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer"., Investigational New Drugs, Vol 23, Pages 123-135 (2005)	
/G.K.	5	Giles, et al., "A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia.", Clinical Cancer Research, Vol. 10, Pages 2908-2917 (2004)	
/G.K./	6	Rice, et al., "Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU.", Biochemical Pharmacology, Vol. 69, Pages 1463-1472 (2005)	
	-		
-	+-		

		Date	05/08/2008
Examiner	/Ganapathy Krishnan/	Considered	
Signature	itial if reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through o	itation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection is estimated to take 120 minutes to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete the public with a process. Any comments on the government of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and T.S. This is the public with a process of the public with a process of the public with a p